Conventional IgG antibodies are powerful tools for many applications. Despite their flexibility, they also encounter limits of feasibility. With their size of 150 kDa they
YUMAB and InSCREENeX are developing an innovative „Mammalian Display“ screening platform to accelerate antibody development. Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology
Rare antibodies with unusual structures and ultra-long CDRs have the potential to bind to difficult-to-access epitopes (e.g., GPCRs, ion channels), and thus offer a unique
In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs. Read more
Automating small-scale purification, e.g., of antibodies, can enable more research, shorten workflows, free up time for other tasks, and standardize results. This application note by
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig,
Company We are YUMAB Career Partnering Services Antibody Libraries Antibody Discovery Antibody Engineering Antibody Humanization Technologies Newsroom Contact Company We are YUMAB Career Partnering Services
THE NEEDA number of therapeutic options have been explored over the course of the COVID-19 pandemic, yet there is still no effective treatment for hospitalized
In cooperation with Enthera, YUMAB generated Ent001, a stabilized IgG4, without the need for bioinformatic engineering to reach an affinity to TMEM in the lower
